Effects of Oral Inflammation on the Levels of Salivary Biomarkers of AMI

描述(由申请人提供)：为支持这一独特的UOL/Cobre合作而建议的项目将在英国医院和贝勒医学院医院对新诊断的急性心肌梗死患者进行临床研究。根据UOL父母基金最初资助期间的结果，需要检验的假设是：“选定的急性心肌梗死唾液生物标志物水平受牙周病的程度/严重程度的影响，但该水平仍可区分急性心肌梗死”，并包含两个具体目标：目的1：实施一项表征急性心肌梗死患者牙周疾病的临床研究；以及目标2：检验选定的急性心肌梗死唾液生物标志物受牙周病影响的假设。具体来说，我们将从英国医院招募75名急性心肌梗塞患者，从贝勒医学院招募150名急性心肌梗死患者。急性心肌梗死患者将在入院12小时内提供血清血液样本、未受刺激的全唾液样本和使用Aware Messengerd)系统采集的口腔液体样本。患者在大约4到6周后由他们的心脏病专家重新任命以评估他们的心脏状况。此时，我们还将为每位患者安排一次全面的牙周检查和粘膜炎症评估。所有生物体液样本将被分析与心血管疾病和急性心肌梗死诊断相关的生物标志物，包括CRP、IL-lft、MMP-9、TNFEI、BNP、CK-MB、MYO、TNL、MPO、MMP9、d-Dimer、ApoA1、sICAM-1。这一竞争性修订补充资金将提供一个快速扩展在最初的UOL颁奖间隔期间获得的观测文件的机会。此外，RPG与NCRR Cobre奖的跨学科活动之间的这种新型关系将加快记录唾液生物诊断能力的科学研究和假设检验的进展，以帮助快速识别和更有效地干预和管理急性心肌梗死患者。具体地说，这些新资金可以使我们能够迅速实施一项研究，这将是我们的工业合作伙伴LabNow，Inc.将这项技术推向市场的能力的基本要求。 公共卫生相关性：这一竞争性修订将直接与口腔/系统疾病生物学基础中心(CBBO/SD)联系起来，作为NCRR Cobre的一部分，该中心为英国研究人员提供了一个有组织的框架，他们在英国牙科学院的感染、发病机制、宿主反应和细胞生物学方面有着共同的兴趣，专注于口腔-系统疾病的联系，作为其研究组合的一部分，包括与心血管疾病的口腔健康关系。

DESCRIPTION (provided by applicant): The project proposed for support for this unique UOl/COBRE collaboration will implement a clinical research study of newly diagnosed AMI patients at the UK Hospital and Baylor College of Medicine Hospital. The hypothesis to be tested, generated by the outcomes during the initial funding period of the UOl parent grant, is: "Select salivary biomarker levels of AMI are affected by the extent/severity of periodontal disease, but the levels can still discriminate AMI" and incorporates 2 specific aims: Aim 1: Implement a clinical research study characterizing periodontal disease in AMI patients; and Aim 2: Test the hypothesis that select salivary biomarkers of AMI are influenced by periodontal disease. Specifically, we will recruit 75 AMI patients from the UK Hospital and 150 AMI patients from the Baylor College of Medicine. AMI patients will provide a blood sample for serum, a sample of unstimulated whole saliva, and an oral fluid sample collected using the AwareMessengerd) System within 12 hrs of admission. Patients are reappointed at approximately 4 to 6 weeks by their cardiologist to evaluate their cardiac status. At this time, we will also schedule each patient for a complete periodontal examination and mucosal inflammation assessment. All biological fluid samples will be analyzed for biomarkers relevant to cardiovascular disease and AMI diagnosis including, CRP, IL-lft, MMP-9, TNFEI, BNP, CK-MB, MYO, Tnl, MPO, MMP9, d-Dimer, ApoAl, sICAM-1. This competitive revision supplemental funding will provide a rapid opportunity to extend the observational documentation obtained during the initial UOl award interval. Moreover, this novel relationship between the RPG and the interdisciplinary activities of the NCRR COBRE award will accelerate the progress of the scientific research and hypothesis testing in documenting the capacity of salivary biodiagnostics to aid in the rapid identification and more effective intervention and management of AMI patients. Specifically, these new funds can enable us to expeditiously implement a study that will be a fundamental requirement for the capacity of our industrial partner, LabNow, Inc. to bring this technology to market. PUBLIC HEALTH RELEVANCE: This competitive revision will link directly with the Center for the Biological Basis of Oral/Systemic Disease (CBBO/SD) as an NCRR COBRE that has provided an organized framework for research faculty at UK who share common interests in infection, pathogenesis, host responses, and cellular biology in the UK College of Dentistry, that focuses on oral-systemic disease linkages and as part of its research portfolio includes oral health relationships to cardiovascular disease.